big partnering deal imminent, page-29

I'd agree with that. Most likely the initial FDA approval for ATC will be for multi resistant HIV or for those unable to take 3TC, Once licensed for this indication, however, it will be a fairly rapid transition to its use "off label" for first or second line treatment of HIV. Probably the licensing for this would occur more rapidly in Europe (which, obviously,is independent of the FDA, but which may take notice of them) and South East Asia (especially Thailand), both of which are significant markets. Once established as a form of therapy, the trials to expand the indications for its use (e.g as first line therapy) will begin, and be easier to fund from Avexas perspective (some, probably would be run by the NIH NHMRC etc etc). All very exciting.